GlaxoSmithKline Pharmaceuticals Limited

Price Chart

Risk-Adjusted Performance

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Price Performance

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at INR2453.90, up 1.41% from the previous close.

Over the past year, GLAXO has traded between a low of INR2259.50 and a high of INR2863.80. The stock has lost 8.4% over this period. It is currently 14.3% below its 52-week high.

GlaxoSmithKline Pharmaceuticals Limited has a market capitalization of $409.93B, with a price-to-earnings ratio of 40.08 and a dividend yield of 1.75%.

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.